Houman David Hemmati MD Ph D
About
Houman David Hemmati MD Ph D is from Beverly Hills, California, United States. Houman David works in the following industries: "Higher Education", "Hospital & Health Care", "Biotechnology", and "Pharmaceuticals". Houman David is currently Member Board of Directors at Lento Bio, located in New York, United States. Houman David also works as Member Board of Directors at Noveome Biotherapeutics, Inc., a job Houman David has held since Nov 2022. Another title Houman David currently holds is Chief Medical Affairs Officer at Vyluma. In Houman David's previous role as a Member Board Of Directors at MediPrint Ophthalmics , Houman David worked in San Diego, California, United States until Sep 2025. Prior to joining MediPrint Ophthalmics , Houman David was a Vice President of Medical and Clinical Development for New Therapies at Capricor Therapeutics, Inc. and held the position of Vice President of Medical and Clinical Development for New Therapies at Beverly Hills, CA.
Houman David Hemmati MD Ph D's email is available on Finalscout.com free of charge. This database has a wealth of information on over half a billion business professionals and two hundred million companies.
Houman David Hemmati MD Ph D's current jobs
Developing a new class of pharmacological treatments for presbyopia.
Developing a long-acting intravitreal drug delivery platform for treatment of retinal diseases that harnesses the vitreous gel. https://www.optigobio.com
Consult regarding M&A, venture investments, business strategy, and clinical development across all areas of ophthalmology: drug, device, anterior segment, retina, dry eye, pain, and inflammation.
Developing an upper eyelid cream to lift the eyelids and treat both aesthetically unappealing upper eyelid droopiness and blepharoptosis. https://levationpharma.com
Attending Physician, Cornea & Comprehensive Ophthalmology Clinics, Los Angeles County USC Medical Center
Houman David Hemmati MD Ph D's past jobs
Contact lens drug delivery to the eye.
Executive Committee member of publicly-traded clinical-stage biotechnology company. Led and directed strategic, pre-clinical, and clinical efforts to support development of portfolio of biologic products, with a focus on CAP-2003 exosome platform, and guided creation of pipeline to facilitate company success. Spearheaded global patient advocacy and clinical trial recruitment efforts for orphan/rare disease indications, including Duchenne Muscular Dystrophy. Directed business development efforts in exosome space, identifying and interfacing with external partners to accelerate and broaden development efforts. Led ophthalmology, dermatology, and oncology-related therapeutic areas. Helped prepare investor and board presentations. ¥ Identified ophthalmology as lead therapeutic area for exosome platform, leading numerous in-house, academic, and CRO pre-clinical studies globally, leading to successful pre-IND meeting with FDA for this first-in-class therapeutic. ¥ Led pre-clinical and IND-enabling studies in dermatology, radiation injury, and systemic inflammation. ¥ Inventor on 3 patent applications: ocular inflammation, radiation dermatitis, systemic inflammation. ¥ Directed global patient advocacy and recruitment efforts for successful Phase 2 trial of CAP-1002 in Duchenne Muscular Dystrophy, which enrolled significantly faster than projected timelines. ¥ Presented at major national and international meetings regarding cell therapy, Duchenne, exosome, and ophthalmology programs. ¥ Identified and led discussions with potential external partners for exosome program business development. ¥ Recruited top global KOLs in ocular inflammation, radiation injury, and GVHD, and organized successful advisory boards across those therapeutic indications.